Absci Corp
NASDAQ:ABSI
Absci Corp
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
Pipeline Focus: Absci is prioritizing ABS-201 for both androgenetic alopecia (AGA) and endometriosis, citing significant unmet need and larger market opportunities.
ABS-101 Partnering: The company will seek a partner for ABS-101 after Phase I, ending its own clinical development for the asset.
Clinical Milestones: The ABS-201 Phase I/IIa trial in AGA will begin dosing next month, with interim proof-of-concept data expected in the second half of 2026; an endometriosis Phase II trial will start in late 2026 with interim data in the second half of 2027.
Positive Early Data: ABS-201 preclinical and ex vivo data show high potency, low immunogenicity, and support for durable hair regrowth and potential disease-modifying effects in endometriosis.
Financial Position: Absci reported $152.5 million in cash and equivalents at quarter-end, enough to fund operations into the first half of 2028.
Revenue and Expenses: Q3 revenue was $400,000. R&D expenses increased to $19.2 million while SG&A declined to $8.4 million.
Partnership Outlook: Management anticipates signing one or more drug creation partnerships, including with a large pharma company, by year-end.
